

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**

**Aceso Life Science Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 00474)**

**DELAY IN DESPATCH OF CIRCULAR IN RELATION TO  
MAJOR TRANSACTION  
ACQUISITION OF SALE SHARES AND ISSUE OF CONSIDERATION NOTES**

Reference is made to the joint announcement jointly published by Aceso Life Science Group Limited (the “**Company**”) and HTICI dated 28 October 2022 in relation to the major transaction of the Company relating to the acquisition of Sale Shares and issue of Consideration Notes (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As the ALS Acquisition was approved by way of written shareholders’ approval, pursuant to Rule 14.41(a) of the Listing Rules, a circular of the Company (the “**Circular**”) containing, among other information, further details of the Acquisitions and other information as required under the Listing Rules must be despatched within 15 business days after publication of the Announcement, which is on or before 18 November 2022. As additional time is required to prepare and finalize, among other things, the relevant financial information, including but not limited to the indebtedness statement of the Company, for inclusion in the Circular, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules (the “**Waiver**”), it is expected that the despatch of the Circular will be postponed to a date on or before 20 January 2023.

As at the date of this announcement, the Waiver has not been granted by the Stock Exchange, further announcement will be made by the Company as and when appropriate.

By order of the Board  
**Aceso Life Science Group Limited**  
**Fok Chi Tak**  
*Executive Director*

Hong Kong, 18 November 2022

*As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Xu Hai Ying, Dr. Zhiliang Ou, JP (Australia) and Mr. Fok Chi Tak and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.*